See every side of every news story

Published 15 days ago • loading... • Updated 15 days ago

Breckenridge obtains FDA OK for generic Afinitor Disperz

Summary by drugstorenews.com

Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma that requires therapeutic intervention but cannot be curatively resected.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

drugstorenews.com

Breckenridge obtains FDA OK for generic Afinitor Disperz

Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma that requires therapeutic intervention but cannot be curatively resected.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated14 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

drugstorenews.com broke the news in 15 days ago on Friday, February 7, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics